REPL

Replimune is a clinical-stage oncolytic immunotherapy company that, per its own 10-K, has 'not generated any revenue from product sales' and explicitly warns it 'expect[s] to continue to incur significant expenses and increasing operating losses for at least the next several years.' The financial profile confirms this: FY2025 net loss widened to -$247M (from -$216M), operating cash burn ran -$192M, and the accumulated deficit ballooned to -$949M. R&D alone consumed $189M against zero revenue — the entire enterprise is a binary bet on the proprietary RPx platform clearing regulatory and clinical hurdles that the filing does not claim are near.

The balance sheet looks superficially solid ($551M assets, $416M equity, liabilities/equity just 0.33x), but that is an artifact of how the company funds itself: equity issuance. The filing discloses $1,101.8M raised since IPO, including a November 2024 follow-on and a June 2024 private placement, and share count grew 25.5% YoY to 77.1M. Cash of $111M against -$192M operating burn implies well under a year of runway at the current pace — another dilutive raise is effectively mandatory, and management telegraphs it by listing future capital needs across clinical trials, in-house manufacturing, and additional candidates.